A new urine test performed better than PSA-based testing and MRI for monitoring low-risk prostate cancers on active surveillance. Use of the test to determine the need for repeat “monitoring” biopsies would have avoided up to 64% of unnecessary biopsies while maintaining timely detection of higher-grade cancers that merit treatment, according to a study published in The Journal of Urology.
This article was originally published on MedicalXpress.com

